

Area Drugs and Therapeutics Committee Meeting Minutes

Wednesday 16th August 2023 @10am

Microsoft Teams Meeting

Present:	Mehrdad Malekian (MM) Chair Victoria Gemmell (VG) Minutes Gail Richardson (GR) Stephanie Dundas (SD) Tyra Smyth (TS) Kirsty Macfarlane (KM) Carol McGoff (CM)	Emma Harris (EH) David Semple (DS) Colin Angus (lay member)
Apologies:	Christine Gilmour Kelly Baillie	
Declaration of Interest	nil	

Item	Notes	Action
	<u>Minutes/Actions from the last meeting</u> <u>Agreed</u>	
3	<u>Matters Arising</u> New Lay Member Colin Angus was introduced and welcomed as new member of ADTC.	MM
a)	Ogluo-update awaited	MM
b)	IV Contrast This item was discussed, and it was agreed that some additional comments around use in pregnancy and post-delivery TFT's checks in new-borns would be helpful.	MM
c)	Bijuve-awaiting update	MM
d)	Utrogestan-awaiting update	VG
f)	Croup Question regarding dose- to clarify with author. <i>Post Meeting Note:</i> Discussion with Paediatric pharmacist who confirmed that the doses in the guideline are those in current practice both Locally and Nationally. The higher dose is for severe cases and as a last resort prior to ventilation.	VG
g)	PPI In Neonates and Children	

	<p>It was noted that unlicensed medicines listed in BNFC do not need to follow standard UL procedures.</p> <p>Item was agreed pending small typo amendment</p> <p>Typo to be corrected table on p3</p> <p><i>Post Meeting Note-the typo referred is not, it refers to the gauge of enteral tube.</i></p> <p><i>Discussions are ongoing around using the full terminology for clarity</i></p>	
3	<p><u>SMC Advice-CONFIDENTIAL</u></p> <p>Please all see attached Advice from the Scottish Medicines Consortium which will be published on the SMC website after 10am, Monday 7th August</p> <p><u>Full Submissions</u></p> <ul style="list-style-type: none"> • selumetinib hard capsules (Koselugo) Alexion Pharmaceuticals SMC2540 Not Recommended INFO ONLY • baricitinib film-coated tablets (Olumiant) Eli Lilly and Company Limited SMC2572 Not Recommended INFO ONLY • tezepelumab solution for injection in pre-filled syringe (Tezspire) AstraZeneca plc SMC2541 Accepted Restricted with PAS <p>REFER TO RESPIRATORY FOR COMMENT</p> <p><u>Resubmission</u></p> <ul style="list-style-type: none"> • icosapent ethyl soft capsules (Vazkepa) Amarin Pharma Inc SMC2602 Accepted Restricted with PAS <p>REFER TO HYPERLIPIDAEMIA CLINIC DRS VICKERS AND MACDOUGALL</p> <p><u>Ultra Orphan</u></p> <p>nil</p> <p><u>Abbreviated Submissions</u></p> <ul style="list-style-type: none"> • dapagliflozin film-coated tablets (Forxiga) AstraZeneca UK Limited SMC2577 Accepted <p>REFER TO HEART FAILURE SERVICE DRS WEIR, WHITE, PETRIE</p> <p><u>Non Submissions</u></p> <ul style="list-style-type: none"> • aflibercept solution for injection in pre-filled syringe (Eylea) Bayer Plc SMC2612 FOR INFO • dermatophagoides pteronyssinus and dermatophagoides farinae (Acarizax) Alk-Abello Ltd SMC2613 FOR INFO <p><u>Amended Advice</u></p>	CM

- azacitidine film-coated tablets (Onureg®) Bristol Myers Squibb Pharmaceuticals Ltd SMC2533 ACUTE MYELOID LEUKAEMIA
AWAIT WOSCAN ADVICE

belumosudil film-coated tablet (Rezurock) Sanofi SMC2583-chronic graft-versus-host disease (chronic GvHd) **AWAIT WOSCAN ADVICE**

Please all see attached Advice from the Scottish Medicines Consortium which will be published on the SMC website **after 10.00 am on Monday 11 September 2023.**

Full Submissions

daratumumab (Darzalex) Janssen-Cilag Ltd SMC2536 **Accepted with PAS AWAIT WOSCAN ADVICE**

- ibrutinib film-coated tablets (Imbruvica) Janssen-Cilag Ltd SMC2543 **Accepted with PAS AWAIT WOSCAN ADVICE**
- mosunetuzumab concentrate for solution for infusion (Lunsumio) Roche Products Ltd SMC2542 **Not Recommended**

Resubmission

- rimegepant (Vydura) (preventive) Pfizer Limited SMC2603 **Accepted Restricted PREVIOUSLY SENT TO DR GORRIE FOR ADVICE, BUT NO RESPONSE MM TO INVESTIGATE CURRENT SITUATION REGARDING HEADACHE SERVICE**

Ultra Orphan

- eladocagene exuparvovec (Upstaza) PTC Therapeutics Ltd SMC2586 **FOR NOTING**

Abbreviated Submission

- vutrisiran 25mg solution for injection in pre-filled syringe (Amvuttra®) Alnylam Pharmaceuticals SMC2596 **Accepted with PAS FOR NOTING**

Non Submissions

- nivolumab (Opdivo) Bristol-Myers Squibb Pharmaceuticals Ltd SMC2620 **FOR NOTING**
- crizotinib (Xalcori) Pfizer Limited SMC2621 **FOR NOTING**

Deferred Advice

olipudase alfa powder for concentrate for solution for infusion (Xenpozyme®) Sanofi SMC2560 **FOR NOTING**

Amended Advice

tezepelumab solution for injection in pre-filled syringe (Tezspire) AstraZeneca plc SMC2541 **REFER TO RESPIRATORY**

FOR INFORMATION

	<p>Note: Budget Impact templates will be sent to NHS Board contacts and Directors of Pharmacy under separate cover.</p> <p><u>Paediatric Licence Extensions</u> FOR INFO</p>	
4.	<p><u>SMC follow up</u> CM talked the Committee through the SMC follow up which had been previously circulated. Feedback on a number of items is expected in due course. Work is ongoing to update the status of outstanding medicines decisions.</p>	CM
5.	<p><u>Lanarkshire Formulary</u></p> <p>CM talked the Committee through the formulary amendments that had been previously agreed for the respiratory section for Luforbec®, Tiogiva® and Acepiro®.</p> <p>Inhaler and mucolytic changes to be sent for HODs to share. Changes will also be shared with Primary Care.</p> <p>The status epilepticus formulary section was proposed to be updated in line with local guidelines.</p> <p>Rybelsus Formulary amendment-since the stock issues are likely to last at least a further 12 months, it was agreed that the item should be revisited at that point.</p> <p>The Committee ratified the above changes.</p>	<p>CM</p> <p>VG</p>
6.	<p><u>Clinical Protocols</u></p> <p>(a) <u>Psoriasis & eczema pathways</u></p> <p>This was discussed, and some questions raised</p> <ul style="list-style-type: none"> • check medicines included are permitted for use in NHSL. • need to include info around communications to GP around adding items to GP systems • currently these medicines are not listed in the formulary. This is different to other sections using the same medicines. It would be helpful to have these listed under the relevant section <p>Discussion around how this could happen in practice and around the important of a robust governance process.</p> <p>(b) <u>Insulin information poster</u></p> <p>The committee were impressed with this concise, easy to use document. Approved pending removal of reference to UHM. This will be added to the guideline website for ease of access. Request to add to weekly Staff Brief for information once uploaded to the website.</p>	<p>VG</p> <p>GR</p> <p>VG</p>

	<p>(c) <u>Pivmecillinam</u> Pivmecillinam Prescribing Guidance-this is an update, agreed with minor changes. Oral Pivmecillinam Paediatric Dosing-BNFC provides an update on dosing for children. There was also discussion on consideration of including a flowchart and moving prescribing recommendations to the beginning. The document will be reviewed by the team and returned at a later date</p> <p><u>IV Fluids-paediatrics</u></p> <p>(d) Agreed pending removal of reference to UHW and date to be amended To be shared with ED's across NHSL for information To be converted to guideline template and also distributed to trainees in paper format at induction training events</p> <p><u>CD Poster-Quick Reference guide</u></p> <p>(e) It was agreed that simple information on the different kinds of opioid products would be useful in principle but needed further clarification as noted below;</p> <ul style="list-style-type: none"> • who is it aimed at (HCP's/patients?) • how it will be accessed/distributed. • Consider 2 versions, one for HCP's and one for patients/carers 	<p>SD</p> <p>GR</p> <p>GR</p>
7.	<p><u>ADTC New Medicines Decisions</u> These were noted.</p>	
8.	<p><u>Unlicensed Medicines</u></p> <p>(a) Xylocaine Injection for local anaesthesia. Unlicensed version available from Canada. Paperwork relating to this was not available at the time of the meeting. The chair gave an overview, has reviewed the documents and is comfortable with the option presented. GR gave information on the stringent processes that hospital pharmacies follow to ensure suitability of alternative unlicensed product.</p> <p>There was also a request to forfeit specific consent for use of xylocaine in individual patients. This was discussed and agreed that consent should be obtained as per current guidance, unless in emergency cases when it is not possible due to patient condition. Chair will seek clarification on this.</p>	MM
9.	<p><u>Medication and Clinical risk in Lanarkshire</u> https://www.gov.uk/drug-safety-update</p> <p>Hyoscine warning will be flagged in Prescribing Notes Bulletin this month, alongside some additional information on anticholinergic prescribing</p>	EH

10.	<p><u>Regional Cancer Advisory Network</u> NCMAG Quarterly Update-for info NCMAG updated Advice noted by members</p> <p>KM highlighted that there is some variation as to how Boards implement advice from NCMAG. There are plans for a National Round Table discussion to tackle this.</p>	
11.	<p><u>Patient Safety Alerts</u> nil</p>	
12.	<p><u>Lay member related items</u> nil</p>	
13.	<p><u>Correspondence</u></p> <p>(a) <u>ADTC Collaborative</u></p> <p>(i) ADTCC Newsletter FOR INFO</p> <p>(ii) Pharmacy First Consensus Meeting KM fed back on this.</p>	
14.	<p>Pharmacy & NMAHP Prescribing Governance</p>	
15.	<p><u>AOCB</u></p> <p>(a) COVID Guidelines Update These have been reviewed and tidied up on the guidelines website, with obsolete documents reviewed</p> <p>(b) Topical retinoids and oral contraception. This item was discussed and it was agreed that further strengthening of advices to prescribers is required.</p> <p>(c) Lack of current massive PE Guidance was raised as a risk to the organisation. There is draft guidance in progress. It is aimed to get consensus amongst stakeholders and bring guidance to ADTC for approval.</p>	<p>KM</p> <p>KM/VG</p> <p>MM</p>
16.	<p><u>Date of next meeting</u></p> <p>Wednesday 20th September 2023, 10-12.30pm MS TEAMS</p>	

